“Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028” Report Highlights:
- Global Bispecific Antibody Market Opportunity Assessment: > US$ 30 Billion
- Global Bispecific Antibody Market Cumulative Sales Since 2016: > 8 Billion
- Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021)
- Approved Bispecific Antibodies In Market: 7 Antibodies
- Comprehensive Clinical Trials Insight On More Than 600 Bispecific Antibodies In Clinical Trials
- Comprehensive Clinical Trials Insight By Phase, Indications, Organization, Patent
- Detailed Market Sales and Trends Insight Till 2028
- Quarterly & Yearly Sales Insight Of Approved Antibodies From 2066 Till Q2 2022
- Global & Regional Market Analysis
- Ongoing Clinical Trials Assessment by Status, Phase and Region
With major advancement in molecular biology and biomedical research, much research into monoclonal antibodies now targeted on identifying new targets for development and maximizing their efficacy for use in clinical practice. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition with the advent of bispecific antibodies. Bispecific antibodies (BsAb) due to combination of two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. They are designed to combine specificities of two antibodies and simultaneously involved in addressing different antigens or epitopes. Since the approval of Blincyto in 2014, multiple of bispecific antibodies have gained market authorization.</p)
For instance in July 2022, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation (CMA) for Tecvayli (teclistamab) as monotherapy for adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Tecvayli developed by Janssen Pharmaceutical is novel bispecific antibody construct which targets BCMA and CD3. Another, CHMP has also granted condition marketing approval to mosunetuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.
Apart from this, China has also granted marketing approval to first PD-1/ CTLA-4 bispecific antibody. Cadonilimab (AK104) developed byv Akeso Pharmaceutical is a novel, potential next-generation, first-in-class bi-specific PD-1/ CTLA-4 immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma. In June 2022, China NMPA has granted conditional marketing approval to Cadonilimab injection for the treatment of relapsed or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy. The rapid approval of this bispecific antibody construct represents the promising growth of the market in the region during the forecast period.
It has been analyzed that bispecific antibodies are not only being developed for the oncological uses but also the non-oncological which includes rejection of organ transplants and for the treatment of cancer, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. For instance, Vabysmo developed by Roche is a bispecific antibody targeting the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) pathways for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). The entry of novel bispecific antibody construct has demonstrated huge responses in short span of time.</p.
The promising response of bispecific antibodies can also be suggested by their encouraging response in clinical studies. For instance, Innovent Biologics recently announced the encouraging results of phase-I trial of IB1322 (anti-CD47 /PD-L1 bispecific antibody). The company reported that the investigational bispecific antibody construct has shown favorable safety and tolerability profile in patients with advanced solid tumors. Further trials are being initiated to further explore the safety and efficacy of IB1322 in multiple oncological conditions.
As per Kuick Research report findings, it is estimated that the bispecific antibody therapeutics market is growing at a double-digit rate, thus boosting the overall cancer therapeutics market to extreme, especially when compared with other immunotherapies. It is expected that global bispecific antibody cummulative sales will surpass US$ 90 Billion by 2028. Further, trends and opportunities coupled within the market i.e. rise in the number of cancer cases, government favorable policies and many others are tending to drive the growth of the market.